

Special Issue

Recent Scientific Advancements towards a Vaccine against Group A Streptococcus

Message from the Guest Editors

Group A Streptococcus (GAS) is a major global pathogen, disproportionately affecting low- and middle-income countries, particularly through autoimmune sequelae such as acute rheumatic fever and rheumatic heart disease (RHD). The World Health Organization has highlighted the need for a GAS vaccine, with a particular focus on reducing the burden of pharyngitis as a precursor to the prevention of RHD. The focus of this Special Issue is to bring together exciting developments and considerations for vaccine development against GAS, including epidemiological justification for vaccination or support for particular antigens. We invite you to submit your original research, reports or reviews towards the progression of a vaccine against GAS. Topics can include, but are not limited to, the following: (i) candidate antigens, (ii) correlates of protection, (iii) novel delivery methods, (iv) mucosal immunity, (v) field studies of natural infections, (vi) assay development, and (vii) infection models. Dr. Helen Alexandra Shaw

Guest Editors

Dr. Helen Alexandra Shaw

The Medicines and Healthcare Regulatory Agency (MHRA), London, UK

Dr. Helge C. Dorfmueller

School of Life Sciences, University of Dundee, Dundee, Scotland, UK

Deadline for manuscript submissions

closed (20 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/135098

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).